Advanced glycation end products, oxidative stress and diabetic nephropathy by Yamagishi, Sho-ichi & Matsui, Takanori
www.landesbioscience.com  Oxidative Medicine and Cellular Longevity  101
Oxidative Medicine and Cellular Longevity 3:2, 101-108; March/April 2010; © 2010 Landes Bioscience
REVIEW  REVIEW
Introduction
Diabetic nephropathy is the most common cause of end-stage 
renal disease in the world, and could account for disability and 
high mortality rate in patients with diabetes. According to the 
World Health Organization, it is expected that the number of 
patients with diabetes will rise to 370 million by 2030 in the 
world.1 It has also been reported that about 25–40% of type 1 
or type 2 diabetic patients develop diabetic nephropathy within 
20–25 year of the onset of diabetes.2 Large clinical trials such 
as United Kingdom Prospective Diabetes Study (UKPDS) and 
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Diabetes  Control  and  Complications  Trial  (DCCT)  revealed 
that  strict  control  of  blood  glucose  or  blood  pressure  signifi-
cantly  reduced  the  development  and  progression  of  diabetic 
nephropathy in both type 1 and type 2 diabetes.3,4 However, cur-
rent therapeutic options are far from satisfactory, and the effects 
of  intensive  therapy  on  diabetic  nephropathy  are  insufficient. 
Indeed, intensive therapy of blood glucose and/or blood pressure 
is often difficult to maintain and may increase the risk of hypo-
glycemia and/or hypotension in diabetic patients, and number of 
diabetic patients with end-stage renal failure is still increasing in 
industrialized countries. Therefore, development of novel thera-
peutic strategies that could specially target diabetic nephropathy 
is urgently needed.
Various hyperglycemia-induced metabolic and hemodynamic 
derangements, including increased formation of advanced gly-
cation end products (AGEs), enhanced reactive oxygen species 
(ROS) generation and activation of protein kinase C (PKC), polyol 
pathway and renin-angiotensin system (RAS), are considered to 
contribute to the development and progression of diabetic neph-
ropathy.5 However, a follow-up study of DCCT called DCCT-
Epidemiology  of  Diabetes  Interventions  and  Complications 
(DCCT-EDIC) study, has shown that the reduction in the risk of 
progressive retinopathy and nephropathy resulting from intensive 
therapy in patients with type 1 diabetes persisted for at least sev-
eral years, despite increasing hyperglycemia.6,7 Intensive therapy 
during the DCCT resulted in decreased progression of intima-
media thickness and subsequently reduced the risk of nonfatal 
myocardial infarction, stroke, or death from cardiovascular dis-
ease by 57 percent 11 years after the end of the trials.8,9 Further, 
a recent follow-up study of UKPDS called UKPDS80 also has 
shown that benefits of an intensive therapy in patients with type 
2 diabetes are sustained after the cessation of the trial.10 In this 
study, despite an early loss of glycemic differences between inten-
sive and conventional therapy, a continued reduction in microvas-
cular risk and emergent risk reductions for myocardial infarction 
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About 246 million people worldwide had diabetes in 2007. The 
global figure of people with diabetes is projected to increase 
to 370 million in 2030. As the prevalence of diabetes has risen 
to  epidemic  proportions  worldwide,  diabetic  nephropathy 
has become one of the most challenging health problems. 
Therapeutic options such as strict blood glucose and blood 
pressure  controls  are  effective  for  preventing  diabetic 
nephropathy, but are far from satisfactory, and the number of 
diabetic patients on end-stage renal disease is still increasing. 
Therefore,  a  novel  therapeutic  strategy  that  could  halt  the 
progression  of  diabetic  nephropathy  should  be  developed. 
There is accumulating evidence that advanced glycation end 
products (AGEs), senescent macroprotein derivatives formed 
at an accelerated rate under diabetes, play a role in diabetic 
nephropathy via oxidative stress generation. In this paper, we 
review the pathophysiological role of AGEs and their receptor 
(RAGE)-oxidative stress system in diabetic nephropathy.102  Oxidative Medicine and Cellular Longevity  Volume 3 Issue 2
products of tissue AGEs by macrophages, are reported to increase 
in diabetic and non-diabetic subjects with renal dysfunction.33-35 
Since low molecular weight-AGEs are filtered by the kidney and 
then reabsorbed by proximal tubular cells,36 decreased glomeru-
lar filtration rate and tubulointerstitial cell damage could also 
be  involved  in  AGEs  accumulation  in  patients  with  diabetic 
nephropathy. Further, we have previously found that non-Ne-
(carboxymethyl)lysine (CML) AGEs are increased in parallel to 
the severity of diabetic nephropathy in type 1 diabetic patients.37 
AGEs-modified collage levels in the skin are reported to be one 
of the predictors for diabetic nephropathy and correlated with 
the severity of nephropathy in patients with long-standing type 1 
diabetes as well.31,32
Accumulation of AGEs in the kidney may contribute to the 
progressive alteration in renal architecture and loss of renal func-
tion in patients and rodents via various mechanisms, including 
their cross-linking (β-sheets or cross-β structure) properties of 
matrix proteins and activation of the downstream signalings.38-41 
AGE  formation  on  extracellular  matrix  proteins  alters  both 
matrix-matrix and cell-matrix interactions, being involved in dia-
betic glomerulosclerosis. For example, non-enzymatic glycations 
of type IV collagen and laminin reduce their ability to interact 
with negatively charged proteoglycans, increasing vascular per-
meability to albumin.42 Further, AGE formation on various types 
of matrix proteins impairs their degradation by matrix metal-
loproteinases, contributing to basement membrane thickening 
and mesangial expansion, hallmarks of diabetic nephropathy.43,44 
AGEs  formed  on  the  matrix  components  can  trap  and  cova-
lently cross-link with the extravasated plasma proteins such as 
lipoproteins, thereby exacerbating diabetic glomerulosclerosis.44 
AGEs including glycoxidation or lipoxidation products such as 
CML, pentosidine, malondialdehyde-lysine accumulate in the 
expanded mesangial matrix and thickened glomerular basement 
membranes of early diabetic nephropathy, and in nodular lesions 
of advanced disease, further suggesting the active role of AGEs 
for diabetic nephropathy.45
AGEs  induce  apoptotic  cell  death  and  vscular  endothelial 
growth factor (VEGF) expression in human cultured mesangial 
cells, as the case in pericytes, a counterpart of mesangial cells in 
retinas.46 Mesangial cells occupy a central anatomical position in 
the glomerulus, playing crucial roles in maintaining structure and 
function of glomerular capillary tufts.47 They actually provide 
structural support for capillary loops and modulate glomerular 
filtration by its smooth muscle activity.47-49 Therefore, the AGE-
induced mesangial apoptosis and dysfuction may contribute in 
part to glomerular hyperfiltration, an early renal dysfunction in 
diabetes. Recently, antibodies against VEGF have been found to 
improve hyperfiltration and albuminuria in experimental dia-
betes, supproting our speculation.50 Further, we have recently 
found  that  AGEs  stimulate  monocyte  chemoattractant  pro-
tein-1 (MCP-1) expression in mesangial cells.46 Increased MCP-1 
expression associated with monocyte infiltration in mesangium 
has been observed in the early phase of diabetic nephropathy.51 
Urinary MCP-1/creatinine ratios in type 2 diabetic patients with 
microalbuminuria were much higher than those in normal con-
trols, and intensive insulin treatment decreased significantly the 
and  death  from  any  cause  were  observed  during  10  years  of 
post-trial follow-up.10 These observations indicate that intensive 
therapy to control blood glucose has long-term beneficial effects 
(legacy effects) on the risk of diabetic retinopathy, nephropathy, 
cardiovascular disease (CVD) and death in patients with both 
type 1 and type 2 diabetes, strongly suggesting that so-called 
‘metabolic memory’ could cause chronic damage in diabetic ves-
sels that are not easily reversed, even by subsequent, relatively 
good control of blood glucose.
Reducing sugars can react non-enzymatically with the amino 
groups  of  proteins  to  form  reversible  Schiff  bases,  and  then 
Amadori products.5,11-14 These early glycation products undergo 
further complex reactions such as rearrangement, dehydration 
and condensation to become irreversibly cross-linked, heteroge-
neous fluorescent derivatives termed AGEs.5,11-14 The formation 
and accumulation of AGEs have been reported to progress at an 
accelerated rate under diabetes. The pathological role of the non-
enzymatic glycation of proteins has become increasingly evident in 
various disorders including diabetic vascular complications.5,15-19 
Furthermore, there is a growing body of evidence that AGEs 
and their signal-transducing receptor interaction evokes oxida-
tive stress and subsequently elicits vascular inflammation and   
thrombosis, thereby playing a central role in the pathogenesis of 
vascular complications in diabetes.5,20-24
Although the exact pathophysiological mechanisms respon-
sible for a legacy effect of the intensive glycemic control or meta-
bolic memory are unclear, biochemical nature of AGEs, that is, 
gradual accumulation of AGEs under hyperglycemic conditions 
that are subsequently slowly degraded with intensive glycemic 
control, is compatible with the concept ‘metabolic memory’.5,11-14 
Further, AGEs and/or diabetic conditions are shown to upregu-
late receptor for AGEs (RAGE) expression in various cell types 
and induce sustained activation of transcriptional factor nuclear 
factor-κB (NFκB).5,25-27 Therefore, it is conceivable that the AGE-
RAGE-induced  oxidative  stress  generation  further  potentiates 
the formation and accumulation of AGEs under diabetic con-
ditions,28 and these positive feedback loops between AGEs and 
RAGE-downstream pathways could make a vicious cycle, thus 
providing a mechanistic basis for understanding the concept of 
‘metabolic memory’ in vascular complications in diabetes. Since 
the above-mentioned observations suggest that the AGE-RAGE-
induced ROS generation is a novel molecular target for vascular 
complications in diabetes, we review here the pathophysiological 
role of AGE-RAGE-oxidative stress system and its therapeutic 
interventions in diabetic nephropathy.
Role of AGEs in Diabetic Nephropathy
In type 1 and type 2 diabetic patients, serum and tissue AGEs 
levels were significantly increased compared with non-diabetic 
control  subjects.29,30  Further,  diabetic  patients  with  end-stage 
renal disease had almost twice as much AGEs in tissue as dia-
betic patients without renal disease.29 Both enhanced formation 
and decreased clearance are responsible for the accumulation of 
AGEs in patients with diabetic nephropathy.31,32 Indeed, serum 
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interaction can also induce sustained activation of NFκB as a 
result of increased levels of de novo synthesized NFκBp65 over-
riding endogenous negative feedback mechanisms and thus might 
contribute to the persistent damage to diabetic kidney.27
Engagement  of  RAGE  with  AGEs  elicits  oxidative  stress 
generation,  thus  participating  in  diabetic  nephropathy  (Table 
1).5,20-24 Indeed, ROS are cytotoxic to renal cells and promote 
inflammatory and fibrogenic reactions in diabetic kidney.46,56,67-69 
The AGE-RAGE-mediated ROS generation stimulates produc-
tion of pro-sclerotic growth factors such as TGFβ and CTGF 
via  mitogen-activated  protein  kinase  (MAPK),  NFκB  and/or 
PKC  pathways  in  both  mesangial  and  renal  tubulointerstitial 
cells.46,56,67-69 Moreover, Tallas-Bonke et al. have recently reported 
that inhibition of NADPH oxidase by apocynin prevents the 
AGE-elicited renal damage in experimental diabetic nephropathy 
through a PKC-α dependent pathway.70 Therefore, the inhibition 
of NADPH oxidase-derived ROS generation elicited by AGE-
RAGE system may be a novel therapeutic target for the treatment 
of diabetic patients with nephropathy.
TGFβ  is  a  well-known  pro-fibrogenic  factor.71  It  not  only 
stimulates  matrix  synthesis,  but  also  inhibits  matrix  degrada-
tion, being involved in tubuloglomerular sclerosis in diabetes.71 
TGFβ mRNA and protein levels are significantly increased in 
glimeruli and tubulointerstitium in type 1 and 2 diabetic ani-
mals and patients.69,72,73 AGE accumulation in diabetic kidney 
is shown to be closely linked to renal expression of TGFβ55-57,72,73 
and  administration  of  AGEs  was  reported  to  increase  renal 
TGFβ levels in conjunction with increase in AGEs accumula-
tion in diabetic rodents.74 In addition, we have previously found 
that AGEs activate TGFβ-Smad system though the interaction 
with RAGE in cultured mesangial cells.75 Moreover, Oldfield et 
al. have reported that AGEs cause TGFβ-induced epithelial-to-
mesenchymal transdifferentiation via interaction with RAGE in 
normal rat kidney epithelial cell line, NRK 52E cells as well.76 
These observations suggest the pathological role for the AGE-
RAGE axis in glomerular sclerosis and tubulointerstitial fibrosis, 
which is a molecular target for prevention of diabetic nephropa-
thy (Fig. 1). In support of this speculation, inhibition of AGE 
formation by pylidoxamine was shown to reduce renal TGFβ 
mRNA levels in association with decrease in urinary albumin 
excretion rate in KK-A(y)/Ta mice, an animal model of type 2 
diabetes.77 An AGEs-crosslink breaker, ALT-711, or OPB-9195, 
an inhibitor of AGE formation was reported to ameliorate renal 
injury in diabetic animals by suppressing TGFβ overexpression 
in diabetic animals as well.78,79
CTGF has been considered to act as a downstream target of 
TGFβ in diabetic nephropathy.80 Several papers have suggested 
an active role for CTGF in diabetic nephropathy.80-82 CTGF lev-
els in the glomeruli are increased in diabetic animals, and plasma 
levels of CTGF are reported to be elevated in patients with dia-
betic nephropathy.81,82 Further, Twigg et al. have recently found 
urinary MCP-1/creatinine ratios.52 Therefore, AGE accumula-
tion in glomerulus could also be implicated in the initiation of 
diabetic nephropathy by promoting the secretion of MCP-1 in 
mesangial cells.
AGEs  stimulate  insulin-like  growth  factor-I,  -II,  platelet-
derived growth factor and transforming growth factor-β (TGFβ) 
in mesangial cells, which in turn mediate production of type IV 
collagen, laminin and fibronectin.53,54 AGEs induce TGFβ overex-
pression in both podocytes and proximal tubular cells as well.55,56 
Recently, Ziyadeh et al. reported that long-term treatment of type 
2 diabetic model mice with blocking antibodies against TGFβ 
suppressed  excess  matrix  gene  expression,  glomerulosclerosis, 
and prevented the development of renal insufficiency.57 These 
observations suggest that AGE-induced TGFβ expression plays 
an important role in the pathogenesis of glomerulosclerosis and 
tubulointerstitial fibrosis in diabetic nephropathy.58,59
In vivo, administration of AGE-albumin to normal healthy 
mice for 4 weeks has been found to induce glomerular hyper-
trophy with overexpression of type IV collagen, laminin B1 and 
TGFβ genes.60 Furthermore, chronic infusion of AGE-albumin 
to otherwise healthy rats leads to focal glomerulosclerosis, mesan-
gial expansion, and albuminuria.61
Role of RAGE and Oxidative Stress  
in Diabetic Nephropathy
There is accumulating evidence that AGE-RAGE axis is involved 
in the pathogenesis of diabetic nephropathy.55,62-64 Among various 
types of AGE receptors, RAGE is a signal transducing receptor 
for AGEs that could mediate the inflammatory reactions evoked 
by AGEs.5,20-24 In humans, RAGE expression is enhanced in pod-
ocytes and mesangial cells in diabetic patients with nephropa-
thy.62,63 Several animal studies have also supported the crucial 
role for RAGE in the development and progression of diabetic 
nephropathy. Indeed, RAGE-overexpressing diabetic mice have 
been found to show progressive glomerulosclerosis with renal dys-
function, compared with diabetic littermates lacking the RAGE 
transgene.64 Further, Wendt et al. reported that diabetic homozy-
gous RAGE null mice failed to develop mesangial matrix expan-
sion or thickening of the glomerular basement membrane.55 They 
also claimed in their report that activation of RAGE in podocytes 
could contribute to expression of VEGF and enhanced attraction/
activation of inflammatory cells in the diabetic glomeruli, caus-
ing albuminuria and glomerulosclerosis in diabetes.55 In addi-
tion, it has been reported that db/db or streptozotocin-induced 
diabetic  mice  develop  renal  changes  seen  in  human  diabetic 
nephropathy such as glomerular hypertrophy, glomerular base-
ment membrane thickening, mesangial matrix expansion, con-
nective tissue growth factor (CTGF) overexpression, and NFκB 
activation, all of which are blocked by the administration of neu-
tralizing antibody raised against RAGE.65,66 The AGE-RAGE 
Table 1. Downstream pathways of the AGE-RAGE axis in diabetic nephropathy
Intracellular signals Target genes Pathology
ROS, NADPH oxidase activation, NFκB, 
PKC, MAPK
TGFβ, CTGF, Ang II, ICAM-1, VCAM-1, 
VEGF, MCP-1
inflammation, glomerulosclerosis, tubulointerstitial fibrosis, 
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the  pathophysiological  crosstalk 
between the RAS and AGE-RAGE 
axis  in  diabetic  nephropathy. 
Indeed,  we  have  previously  found 
that  AGEs  activate  mesangial 
TGFβ-Smad  system  through  the 
autocrine production of Ang II via 
oxidative stress generation.75 Miyata 
et  al.  have  recently  reported  that 
an ACE-I temocapril and an ARB 
olmesartan  significantly  inhibit  in 
vitro-formation of pentosidine and 
CML.95  In  animal  models,  Forbes 
et  al.  have  reported  that  ACE-I 
decreases circulating and renal tis-
sue levels of AGEs in experimental 
diabetic  nephropathy.93  An  ARB 
reduced  renal  levels  of  AGEs  in 
AGE-injected animals as well, while 
Ang II infusion accelerated the for-
mation and accumulation of AGEs 
in both glomeruli and renal tubules 
in  their  models.94  In  addition, 
administration of olmesartan medoxomil was found to inhibit 
the increase of systolic and diastolic blood pressure levels and 
urinary  N-acetyl-beta-D-glucosaminidase  activity  and  pre-
vent glomerulosclerosis in exogenously AGE-injected rats.96 In 
humans, an ACE-I, ramipril treatment has been shown to result 
in a mild decline of fluorescent non-CML-AGE and malondial-
dehyde concentrations in non-diabetic nephropathy patients.97 
In type 2 diabetic subjects, a low-dose of valsartan treatment 
was reported to decrease serum AGE levels in a blood pressure-
independent manner.98 These observations suggest that benefi-
cial effects of the blockade of the RAS on diabetic nephropathy 
could be ascribed at least in part to its inhibitory effects of the 
AGE-RAGE-oxidative stress system.
Several papers have shown that peroxisome proliferator-
activated receptor-γ  (PPARγ) agonists block the deleterious 
effects of AGEs and exert beneficial actions on diabetic neph-
ropathy.99-110  Indeed,  activation  of  PPARγ  by  rosiglitazone 
inhibited AGE-induced inducible nitric oxide (NO) synthase 
expression, nitrite release, fibronectin and type IV collagen 
production by mesangial cells.99,100 Rosiglitazone attenuated 
the  AGE-induced  interleukin-8  and  soluble  intercellular 
adhesion molecule-1 (ICAM-1) generation by proximal tubu-
lar epithelial cells as well through the suppression of signal 
transducer and activator of transcription (STAT).101 Further, 
rosiglitazone was reported to inhibit renal extracellular matrix 
accumulation, fibronectin, type IV collagen and plasminogen 
activator  inhibitor-1  (PAI-1)  production  and  subsequently 
reduce proteinuria in AGE-injected rats.101
Suppression of RAGE expression may be a molecular tar-
get of PPARγ agonists.102-111 Marx et al. reported that stimu-
lation of human endothelial cells with PPARγ agonists such 
as  rosiglitazone  and  pioglitazone  decreased  basal  as  well 
as  tumor  necrosis  factor-alpha-induced  RAGE  expression 
that an inhibitor of AGEs, aminoguanidine decreases renal CTGF 
and fibronectin levels in experimental diabetic nephropathy.82 
They also showed that ALT-711 reduced renal CTGF levels in 
their models.82 Since CTGF also plays a role in the AGE-induced 
epithelial-to-mesenchymal transdifferentiation,83 suppression of 
CTGF expression may be a potential therapeutic target for tubu-
loglomerulosclerosis in diabetic nephropathy.
Therapeutic Interventions  
of the AGE-RAGE-Oxidative Stress System  
in Diabetic Nephropathy
Several large clinical studies have reported the potential utility 
of angiotensin-converting enzyme inhibitors (ACE-Is) or angio-
tensin II (Ang II) type 1 receptor blockers (ARBs) for the treat-
ment of hypertensive diabetic patients with microalbuminuria or 
overt nephropathy (Table 2).84-88 Although blood pressure-low-
ering property could largely explain the beneficial effects of these 
agents on diabetic nephropathy, there is accumulating evidence 
to suggest that ACE-Is or ARBs may exert salutary effects on 
diabetic nephropathy, at least in part, by blocking the pathologi-
cal crosstalk between the RAS and the metabolic pathways such 
as AGE-RAGE axis.89 Indeed, angiotensinogen production by 
cultured proximal tubular cells is increased in response to high 
glucose concentration, and the intrarenal Ang II level is signifi-
cantly higher than that in serum in patients with diabetic neph-
ropathy.90,91 Further, high glucose stimulates Ang II generation 
in  association  with  increased  TGFβ1  production  by  cultured 
mesangial cells.92
Since  Ang  II  increases  intracellular  ROS  generation  in 
renal cells, it may stimulate the production of AGEs and fur-
ther  augment  the  AGE-RAGE  system  in  diabetic  kidney.93-98 
There is accumulating in vitro- and in vivo-evidence to suggest 
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overexpression of TGFβ, a major pathogenic factor in diabetic 
nephropathy, and fibronectin in primary cultured mesangial 
cells.120 Therefore, decreased expression of PEDF in diabetic 
kidneys could contribute to extracellular matrix overproduc-
tion  and  the  development  of  diabetic  nephropathy.  In  vivo, 
overexpression of PEDF was found to alleviate microalbuminu-
ria, to prevent the expression of two major fibrogenic factors, 
TGFβ and CTGF, and to significantly reduce the production 
of  an  extracellular  matrix  protein  in  the  diabetic  kidney.121 
Moreover,  PEDF  upregulated  metalloproteinase-2  expression 
in diabetic kidney, which is responsible for extracellular matrix 
degradation. Taken together, these findings suggest that PEDF 
functions as an endogenous anti-TGFβ and anti-fibrogenic fac-
tor in the kidney. A therapeutic potential of PEDF in diabetic 
nephropathy is supported by its downregulation in diabetes, its 
prevention of the overexpression of TGFβ, CTGF and extra-
cellular matrix proteins accumulation in diabetic kidney and 
its amelioration of albuminuria. Since we have recently found 
that PEDF inhibits the AGE-induced vascular permeability by 
blocking the ROS-mediated VEGF expression,114,115 the salutary 
effects of PEDF on proteinuria may be ascribed partly to its 
inhibitory actions on the AGE-signaling to VEGF expression 
in diabetic nephropathy.
Conclusion
In this paper, we review the pathophysiological role of AGE-
RAGE-oxidative  stress  in  diabetic  nephropathy.  Inhibition  of 
the AGE formation and/or the blockade of RAGE-downstream 
pathways will be a promising therapeutic strategy for the treat-
ment of diabetic patients with nephropathy.
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via suppression of NFκB activation. They also showed that 
PPARγ agonists decreased AGE-induced MCP-1 expression 
in endothelial cells.102 Further, we have found that telmisar-
tan, an ARB, downregulates RAGE expression and suppresses 
its downstream signalings in various cell types through its 
unique  PPARγ-modulating  ability.104-109  Indeed,  telmisartan 
was found to reduce RAGE mRNA levels and subsequently 
inhibit  superoxide  generation  as  well  as  MCP-1  expression 
in mesangial cells, all of which were prevented by GW9662, 
an inhibitor of PPARγ.106 In addition, we have recently found 
that nifedipine, but not amlodipine, a control calcium chan-
nel blocker, decreased RAGE mRNA levels and subsequently 
reduced  ROS  generation,  and  vascular  cell  adhesion  mol-
ecule-1 (VCAM-1) and MCP-1 expression in AGE-exposed 
mesangial cells, all of which were blocked by the simultaneous 
treatment of GW9662.111 Although nifedipine did not affect 
expression  levels  of  PPARγ,  it  increased  the  PPARγ  tran-
scriptional activity in mesangial cells. Taken together, these 
observations provide unique beneficial aspect of telmisartsan 
and nifedipine on diabetic nephropathy; it could work as an 
anti-inflammatory agent against AGEs by suppressing RAGE 
expression in cultured mesangial cells via PPARγ activation.
Pigment epithelium-derived factor (PEDF) is a glycoprotein 
that belongs to the superfamily of serine protease inhibitors 
with complex neurotrophic, neuroprotective, anti-angiogenic, 
anti-oxidative and anti-inflammatory properties, any of which 
could potentially be exploited as a therapeutic option for the 
treatment of vascular complications in diabetes.112-119 There are 
a couple of papers to suggest the protective effects of PEDF 
against diabetic nephropathy.120,121 PEDF was decreased at both 
the mRNA and protein levels in the kidney of diabetic rats, 
whereas TGFβ and fibronectin levels were increased in the same 
diabetic kidneys.120 In vitro-studies showed that high concen-
trations of glucose significantly decreased PEDF secretion in 
primary  human  glomerular  mesangial  cells,  thus  suggesting 
that hyperglycemia is a direct cause of the PEDF decrease in 
the kidney. Further, PEDF blocked the high-glucose-induced 
Table 2. Clinical trials of the RAS inhibitors in diabetic nephropathy
Agents Subjects Clinical outcomes
Captopril vs. placebo 
(ref. 84)
Type 1 diabetic patients with proteinuria 
more than 500 mg/day
Captopril treatment was associated with a 50 percent reduction in the 
risk of the combined end points of death, dialysis, and transplantation.
Enalapril vs. placebo 
(ref. 85)
Normotensive, type II diabetic patients with 
microalbuminuria and normal renal function
Enalapril treatment resulted in long-term stabilization of plasma 
  creatinine levels and of the degree of urinary loss of albumin.
Irbesartan vs. placebo 
(ref. 86)
Hypertensive patients with type 2 diabetes 
and microalbuminuria
5.2% in the 300-mg group and 9.7% in the 150-mg group reached the 
primary end point (the time to the onset of diabetic nephropathy), as 
compared with 14.9% in the placebo group; hazard ratios were 0.30 and 
0.61 for the two irbesartan groups, respectively. 
Irbesartan vs. 
  amlodipine vs. placebo 
(ref. 87)
Hypertensive patients with nephropathy 
due to type 2 diabetes
Irbesartan treatment was associated with a risk of the primary composite 
end point (a doubling of the base-line serum creatinine concentration, 
the development of end-stage renal disease, or death from any cause) 
that was 20% lower than that in the placebo group and 23% lower than 
that in the amlodipine group.
Losartan vs. placebo 
(ref. 88)
Type 2 diabetic patients with nephropathy
Losartan treatment significantly reduced the risk of the primary outcome 
(the composite of a doubling of the base-line serum creatinine concen-
tration, end-stage renal disease, or death).106  Oxidative Medicine and Cellular Longevity  Volume 3 Issue 2
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